Day 2 Agenda | Allogeneic Cell Therapies Summit 2022

Grand Ballroom I and II

8:00 am Coffee Room Networking

8:50 am Chair’s Opening Remarks

Deyaa Adib CMO, Triumvira Immunologics

9:00 am Industry Leaders Fireside Chat

Blake Aftab CSO, Adicet Bio
Pascal Touchon CEO, Atara Biotherapeutics
Carrie Brownstein CMO, Cellectis
Barbra Sasu CSO, Allogene

Synopsis

An executive panel discussion from leaders in the allogeneic cell therapy field
Understand their thoughts about autologous vs allogeneic, and the future of the cell therapy field
Ask your questions to understand expert’s thoughts on key topics including gene engineering, moving into the clinic, CMC, super donors and more

10:00 am The Patient Experience: Solid Tumor Cell Therapies in the Context of Standard Care

Brian Van Tine Professor, Medicine & Pediatrics, Washington University School of Medicine in St. Louis

Synopsis

Review how allogeneic cell therapies impact patients in comparison to approved treatments
Evaluate methods to measure clinical benefit such as survival and quality of life
Understand the importance of considering more than a cost-benefit analysis

10:30 am Industrializing Allogeneic-Based Cell & Gene Therapies

Marcos Langtry Head of Commercial Development Allogeneic Cell Therapy, Lonza

Synopsis

A standardized, systematic approach to commercialization
Challenges and solutions for cGMP manufacturing
Current and future technologies

11:00 am Morning Refreshment Break

Track 1: Pre-Clinical

Chair: Colleen Delaney, Founder, CSO & EVP, Research & Development, Deverra Therapeutics

Ballroom I

Promises & Challenges of Allogeneic Therapies for Solid Tumors

12.00 TCR-NK Cells: A Novel Platform Combining Specific TCR Targeting with Broad NK Cell Cancer Activity

• Reviewing current challenges in targeting solid tumors
• TCR-NK cells as novel, safe and potent offthe- shelf therapies for solid tumors
• Potential of TCR-NK cells to overcome tumor escape mechanisms

Luise Weigand, Head of Research, Zelluna Immunotherapy

12.30 Developing the Next Wave of Allogeneic CAR T-cells to Defeat Solid Tumors

• Insights into optimized design of allogeneic CAR-T therapies
• TALEN®: an optimal scaffold to equip CAR T-cells with enhanced persistence, potency, and safety
• Next-generation allogeneic CAR T-cell therapies: harnessing multiplex TALEN® editing and addressing the hostile microenvironment to combat solid tumors

Beatriz Aranda-Orgilles, Senior Scientist & Team Leader Immuno-Oncology, Cellectis

1.00 Lunch Refreshment Break

Exploring Approaches to Best Target Cancer Cells

2.00 Precision Targeting of AML with Logic Gated CAR-NK Cells

• Reviewing SENTI-202, a candidate designed to broadly target AML tumor cells while sparing healthy hematopoietic stem and progenitor cells
• Demonstrating enhanced killing of AML lines in primary patient samples in vitro, and multiple xenograft models in vivo
• Showing antigen specific protection of model healthy cells from off-tumor killing

Gary Lee, CSO, Senti Biosciences

2.30 Allogeneic G-NK Cells Combined with Monoclonal Antibodies for Enhanced Tumor Targeting

• Reviewing allogeneic FcεRIγ-deficient G-NK cells that can be combined with any FDA-approved IgG monoclonal antibody to target any kind of cancer
• Exploring the properties that make them idea for combination with anti-CD38 antibodies for the treatment of multiple myeloma
• Outlining pre-clinical outcomes that show enhanced in vivo efficacy, improved persistence and regression of established tumors

Austin Bigley, VP, Director of Research & Development, Indapta Therapeutics

Track 2: Translational

Chair: Erika von Euw, VP, Translational Research, Deverra Therapeutics

Ballroom II

Exploring the Need for Pre-Conditioning Strategies to Improve Engraftment

12.00 Universal Gene Modification Strategies to Obviate the Need for Immunosuppressive Agents

• No gene editing: eliminating the need to modulate HLA Class I and/or II expression
• Allowing for utilization in transient or permanent settings
• Abrogating the need for lymphodepletion and pre-conditioning

Evren Alici, Head of Cell & Gene Therapy, Karolinska Institutet

12.30 Roundtable Session: To Lymphodeplete or Not to Lymphodeplete?

• Are current lymphodepletion regimens up to scratch?
• Should alternate regimens be used for allogeneic products?
• Is lymphodepletion necessary?

Christina Coughlin, CEO, CytoImmune Therapeutics

1.00 Lunch Refreshment Break

Novel Ideas for the Translation of Allogeneic Cells for Therapeutic Use

2.00 A Novel iPSC for Allogeneic Therapeutic Use

• Human Trophoblast Stem Cell-derived iPSC
• Scalable, ethical, unencumbered, stem cell source
• Source for potent NK cells

Sicco Popma, CEO, IO Biosciences

2.30 New Class of Cancer Vaccine Based on a Off-the-Shelf Antigen Presenting Cell Line

• Reviewing our new and scalable therapeutic cancer vaccines based on a propietary allogeneic cell line of plasmacytoid dendritic cells
• Describing how PDC*line is a more potent to prime and boost anti-tumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
• Outlining clinical data and how we aim to translate the technology for new cancer indications

Eric Halioua, CEO, PDC*Line Pharma

Track 3: Manufacturing

Chair: Michael Leek, Co-Founder & Executive Chairman, TC BioPharm

North Shore Ballroom B

Achieving Reproducibility & Comparability in Allogeneic Manufacture

12.00 Ensuring Product Quality and Consistency in Manufacture of Off-the-Shelf Products

• Developing tools to assess the product’s function and safety attributes
• Increasing batch to batch consistency through tightly controlled process design

Martin Giedlin, VP, Head of Technical Operations, Senti Biosciences

12.30 The Evolution of an Allogeneic Process Whilst in the Clinic

• Summarizing results from multiple clinical programs
• Outlining methods to keep process development aligned with clinical data
• Achieving comparability and reproducibility in manufacture to streamline process towards commercialization

Brian Culley, CEO, Lineage Cell Therapeutics

1.00 Lunch Refreshment Break

Setting Up for Late Stage or Commercial Manufacture

2.00 Considerations for the Design of a Cost-Effective Commercial Facility

• Planning for commercial manufacture of an allogeneic product
• Discussing how manufacture must be dependent on indication and demand
• Exploring the possibilities and requirements to improve cost of goods

James Glover, SVP, Commercial Manufacture, Athersys

2.30 Preparing for Commercialization of an Off-the-Shelf Product

• Determining how to upscale from clinical trials to a commercial scale facility
• Exploring the associated opportunities and challenges for manufacturers and their suppliers
• Predicting the evolution of the allogeneic cell therapy landscape over the coming decade

Daniel Bright, Global Program Director of Global Technical Operations, Ferring Pharmaceuticals

Track 4: Supply/Storage

Chair: Arthur Stril, CBO, Cellectis

North Shore Ballroom C

Technology Ecosystem for Supply

12.00 Combining CMC and Clinical Development to Build an Effective Allogeneic Supply Chain

• Bridging CMC, clinical, and regulatory needs to enable scalable delivery of engineered cells
• Controlling and managing a complex network of suppliers and manufacturing partners
• Implementing an effective strategy to ensure end-to-end visibility through complex product journey

Tim Jansen, Director, Supply Chain Strategic Sourcing, Sana Biotechnology

12.30 Transitioning Supply Chains to Fit an Off-the-Shelf Model in Preparation for Clinical Operations

• Distinguishing the necessary changes to supply chain to transition to an allogeneic pipeline
• Assessing complexities in the supply chain when preparing for clinical trials

Rakibou Ouro-Djobo, Associate Director, Clinical Supply Chain, TCR2 Therapeutics

1.00 Lunch Refreshment Break

Addressing Current Challenges in Allogeneic Cell Therapy Supply Chains

2.00 Roundtable Session: Troubleshooting Methods to Address the Global Supply Chain Crisis

• How has this crisis impacted your supply chain?
• Which risk mitigation strategies have you trialed and were they effective?
• What outsourcing/internalization strategy should we adopt across the supply, storage, and distribution supply chain?

Nathan Jorgensen, CFO, Vor Biopharma

2.30 Roundtable Session: Discussing Supply Models to Improve Access to Allogeneic Cell Therapies

• Which innovative storage and distribution models can be envisioned to broaden access?
• How can we deliver these therapies to community centres and developing countries?
• What challenges do we expect to encounter when attempting to improve access?

Arthur Stril, CBO, Cellectis

3:00 pm Afternoon Refreshment Break & Networking

3:30 pm Allogeneic Genome-Engineered HSCT Enabling Post-Transplant Targeted Therapies

Robert Ang CEO, Vor Biopharma

Synopsis

Concept of creating treatment-resistant stem cell transplants via gene deletion of cell surface targets
Implementing next-generation allogeneic healthy donor material supply chain to GMP engineered HSC transplants
Coupling genome-engineered HSCT with CAR-T and beyond

4:00 pm A Full Landscape Overview of the Allogeneic Cell Therapy Space

Bertie MacArthur Account Manager, Beacon Targeted Therapies

Synopsis

Assessing how allogeneic cell therapies align with the rest of the cell therapy landscape
What does the existing allogeneic landscape consist of and how has it changed over recent years
Insights into potential trends and the potential future of allogeneic therapies for oncology

This Meeting has Run

Get Updates About the 2023 Version Here

Day One

Day Two

Grand Ballroom I and II

8:00 am Coffee Room Networking

8:50 am Chair’s Opening Remarks

9:00 am Industry Leaders Fireside Chat

Synopsis

10:00 am The Patient Experience: Solid Tumor Cell Therapies in the Context of Standard Care

Synopsis

10:30 am Industrializing Allogeneic-Based Cell & Gene Therapies

Synopsis

11:00 am Morning Refreshment Break

3:00 pm Afternoon Refreshment Break & Networking

3:30 pm Allogeneic Genome-Engineered HSCT Enabling Post-Transplant Targeted Therapies

Synopsis

4:00 pm A Full Landscape Overview of the Allogeneic Cell Therapy Space

Synopsis

4:30 pm Closing Remarks & Close of Conference

OUR CONTACT DETAILS

ABOUT US

LOCATION

SEARCH